Link Biologics strengthens IP position for Link_TSG6 with US patent Notice of Allowance and University of Manchester IP assignment
Secures long‑term ownership and protection of Link_TSG6, strengthening its global IP position in key markets De‑risks development and enhances long‑term value, supporting advancement towards clinical development London, UK – 6 May 2026 – Link Biologics (“Link” or “the Company”), the biotech company developing first-in-class TSG-6-based therapies that have a unique combination of anti-inflammatory, tissue-protective and […]
